Trevi Therapeutics (TRVI) Earnings Date & Reports

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

TRVI is expected to report earnings to rise 16.64% to -12 cents per share on November 11

Trevi Therapeutics TRVI Stock Earnings Reports

Q3'26

Est.

$-0.13

Q2'26

Missed

by $0.01

Q1'26

Missed

by $0.01

Q4'25

Beat

by $0.04

Q3'25

Beat

by $0.02

The last earnings report on August 06 showed earnings per share of -10 cents, missing the estimate of -10 cents. With 1.47M shares outstanding, the current market capitalization sits at 2.15B.

View a ticker or compare two or three

TRVI

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

View AI-Driven Trading for TRVI